Versor Investments LP Makes New Investment in BioLife Solutions, Inc. $BLFS

Key Points

• Versor Investments LP acquired 18,600 shares of BioLife Solutions, Inc. valued at approximately $425,000, marking a significant investment in the medical equipment provider.
• Analysts have mixed ratings on BioLife Solutions, with Stephens setting a price target of $30.00 and Zacks upgrading to a "strong-buy" rating, while one firm downgraded their rating to "sell."
• BioLife Solutions reported a quarterly earnings miss, with a loss of ($0.33) EPS compared to the consensus estimate of ($0.02), although revenues outperformed expectations at $25.42 million.

Versor Investments LP acquired a new position in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,600 shares of the medical equipment provider's stock, valued at approximately $425,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC grew its holdings in BioLife Solutions by 18.6% in the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock worth $96,000 after purchasing an additional 663 shares during the period. SG Americas Securities LLC grew its holdings in BioLife Solutions by 21.6% in the first quarter. SG Americas Securities LLC now owns 19,136 shares of the medical equipment provider's stock worth $437,000 after purchasing an additional 3,405 shares during the period. Rhumbline Advisers grew its holdings in BioLife Solutions by 0.7% in the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after purchasing an additional 566 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider's stock worth $1,835,000 after purchasing an additional 8,258 shares during the period. Finally, Principal Financial Group Inc. lifted its stake in shares of BioLife Solutions by 6.2% in the first quarter. Principal Financial Group Inc. now owns 259,488 shares of the medical equipment provider's stock worth $5,927,000 after buying an additional 15,241 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Price Performance

BioLife Solutions stock remained flat at $25.65 during midday trading on Tuesday. 541,408 shares of the company were exchanged, compared to its average volume of 576,652. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of -213.73 and a beta of 1.76. The company's 50 day simple moving average is $22.47 and its 200 day simple moving average is $23.38. BioLife Solutions, Inc. has a 12 month low of $19.10 and a 12 month high of $29.55.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. BioLife Solutions has set its FY 2025 guidance at EPS. Sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BioLife Solutions news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total value of $23,800,000.00. Following the transaction, the insider directly owned 7,707,165 shares in the company, valued at approximately $183,430,527. This trade represents a 11.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,008,831 shares of company stock valued at $47,499,658 in the last 90 days. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Zacks Research upgraded shares of BioLife Solutions to a "strong-buy" rating in a research note on Monday, August 11th. Stephens assumed coverage on shares of BioLife Solutions in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 target price on the stock. HC Wainwright reiterated a "buy" rating and issued a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. One equities research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.